Home Science > Pipeline

Pipeline

Where there’s a will, there’s a way. Patients are our will.

Pipeline

PRE-CLINICAL
Undisclosed targets
Neuroscience
Undisclosed targets
Cannabinoids
CombiPlex
Exploratory activities
Undisclosed target
Ras/Raf/MAP kinase pathway1
JZP898 (WTX-613)2
Conditionally-activated IFNα
Undisclosed targets
Oncology
PHASE 1
JZP3243
Oxybate extended-release formulation
JZP441 (DSP-0187)2
Orexin-2 receptor agonist
Additional Cannabinoids
Neuropsychiatry targets
JZP815
Pan-Raf Inhibitor Program
Raf & Ras mutant
Zanidatamab2
HER2-targeted bispecific antibody
Breast cancer
JZP341
(Long-acting Erwinia asparaginase)
Solid tumors
JZP351 (Vyxeos)
Low Intensity Dosing for higher risk MDS4
JZP351 + other approved therapies
  • R/R AML or HMA Failure MDS4
  • First-line, fit AML (Phase 1b)
PHASE 2
Suvecaltamide (JZP385)
Essential tremor
Suvecaltamide (JZP385)
Parkinson’s Disease Tremor
JZP1505
PTSD
JZP541

Irritability associated with autism spectrum disorders
Additional Cannabinoids

Autism spectrum disorders
Zanidatamab2
HER2-targeted bispecific antibody
  • 2L zani monotherapy for BTC6 (Pivotal trial)
  • Additional trials ongoing in BTC, GEA and CRC
  • Multiple trials ongoing in breast cancer
JZP351
  • HR-MDS (EMSCO)7
  • Newly diagnosed older adults with HR-AML7
JZP351 + venetoclax
de novo or R/R AML4
PHASE 3
Cannabidiol (Epidyolex)
LGS, DS, TSC in Japan

Zanidatamab2
HER2-targeted bispecific antibody
1L zani + chemo ± tislelizumab for GEA8
(Pivotal trial)

Lurbinectedin1
1L treatment SCLC in combination with Tecentriq® (atezolizumab)
JZP351
  • AML or HR-MDS >60 yrs (AML18)7
  • Newly diagnosed adults with standard- and HR-AML (AMLSG)7
  • Newly diagnosed <22 yrs with AML (COG)7
REGULATORY
JZP458 (Rylaze)9
(recombinant Erwinia asparaginase)
ALL/LBL
Neuroscience
Oncology
1Partnered collaboration;
2Acquired;
3Planned;
4Jazz & MD Anderson Cancer Center collaboration study;
5JZP150 is a fatty acid amide hydrolase inhibitor which modulates the endocannabinoid anandamide;
6HERIZON-BTC-01;
7Cooperative group study;
8HERIZON-GEA-01;
9FDA approval on June 30, 2021 and FDA approval of sBLA for MWF IM dosing on November 18, 2022. Positive CHMP opinion July 21, 2023.

1L = first line, ALL/LBL = acute lymphoblastic leukemia / lymphoblastic lymphoma, AML = acute myeloid leukemia, COG = Children’s Oncology Group, BTC = biliary tract cancer, CRC = colorectal cancer, DS = Dravet syndrome, GEA = gastroesophageal adenocarcinoma, HMA = hypomethylating agents, HR = high-risk, HRD+ = homologous recombinant deficient positive, LGS = Lennox-Gastaut syndrome, MDS = myelodysplastic syndromes, PTSD = post-traumatic stress disorder, R/R = relapsing/refractory, SCLC = small cell lung cancer, SG = study group, TSC = Tuberous sclerosis complex.